November 9, 2016
1pm EST to 2pm EST

Sponsored by

Webinar Description:

Neurohistology in Research and Preclinical Drug Development – How Tissue Analysis Can Enhance Experimental Endpoints. Preclinical studies rely on key experimental data for demonstrating therapeutic efficacy. Understanding disease or therapeutic induced changes at tissue and cellular levels can significantly impact study outcomes. This webinar is intended to provide participants with a comprehensive overview of how established neurohistology techniques can be utilized to assess therapeutic efficacy and understand possible mechanism of action.

Learning Objectives:

• Neurohistology in research & development
• How does histology aid drug discovery and development
• Why are reliable and reproducible experimental readouts critical
• Quantitative vs. qualitative assessments
• Challenges & new developments

Speakers:

Robin Avila, Ph.D.

Scientist and Manager of Strategic Alliances

Renovo Neural, Inc.

Dr. Avila is a Scientist and Strategic Alliance Manager at Renovo. She has over 10 years of experience in research and drug development in neuroscience specializing in myelin biology and development of preclinical models of multiple sclerosis. She has an extensive background with projects ranging from structural biochemistry using X-ray diffraction to characterize central and peripheral nervous system myelin defects to molecular genetics, studing the genes that regulate myelination and remyelination. She has a strong track record of peer reviewed publications and presentations at scientific conference. Dr. Avila received a BS in Biology from the University of Vermont, a PhD in Biology/Structural Biochemistry from Boston College.

Simon Lunn, Ph.D.

Director of Operations

Renovo Neural Inc.

Dr. Lunn is a Scientist and Director of Operations at Renovo where he project manages all neurohistological studies and analysis for research and drug development studies. He has an extensive background working to develop regenerative therapies for neurodegerative diseases such as ALS and Alzheimer’s disease. He has several authored publications utilizing and developing neurohistologicial approaches to answer complex questions involved in neuroprotection, axon degeneration, regeneration, and neuromuscular functions. Dr. Lunn received his BS in Biochemistry from The University of Glasgow, and a PhD in Neural Biology from The University of Dundee.